Compass Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Compass Therapeutics's estimated annual revenue is currently $6M per year.
- Compass Therapeutics received $132.0M in venture funding in July 2018.
- Compass Therapeutics's estimated revenue per employee is $143,929
- Compass Therapeutics's total funding is $176.5M.
- Compass Therapeutics has 42 Employees.
- Compass Therapeutics grew their employee count by 20% last year.
Compass Therapeutics Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Compass Therapeutics?
Were building Compass with a singular goal in mind: unlocking the complexity of the immune system. Our discovery and development teams work together to fully characterize and evaluate novel antibodies and rapidly generate therapeutic candidates. We are leveraging those insights to develop transformational therapies for cancer, inflammation and autoimmune diseases. We are a privately held company; our financing has been led by OrbiMed Advisors, F-Prime Capital, Cowen Healthcare Investments, Thiel Capital, Biomatics Capital, Borealis Ventures, Alexandria Real Estate Ventures and Biomed Realty Ventures. To learn more, visit www.compasstherapeutics.comkeywords:N/A
Number of Employees
Employee Growth %
Compass Therapeutics News
BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biotechnology...
BOSTON, March 21, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical...
BOSTON--(BUSINESS WIRE)--Mar 5, 2021-- Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today reported fourth quarter and ...
BOSTON--(BUSINESS WIRE)--Mar 4, 2021-- Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, announced today that shares of the ...
Compass Therapeutics, a Cambridge, MA-based biotechnology company committed to comprehensively drugging the human immune system, closed the final $49m tranche of its $132m Series A financing. The round was led by OrbiMed Advisors and included F-Prime Capital, Cowen Healthcare Investments, Thiel ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Compass Therapeutics Funding